

**APPENDIX**  
*Pending Claims*

1. A particulate drug delivery composition for intranasal delivery comprising a plurality of bioadhesive microspheres and a systemically active drug, wherein at least 90 wt % of the microspheres of the composition have a diameter of between 0.1  $\mu\text{m}$  and 10  $\mu\text{m}$ , and wherein the composition is capable of systemic delivery of a therapeutically effective amount of the drug to a mammal upon intranasal administration.
2. A drug delivery composition according to Claim 1 wherein the microspheres are prepared from a material that will gel in contact with the mucosal surface.
3. A drug delivery composition according to Claim 1 or 2 wherein the microspheres comprise starch, gelatin, albumin, collagen, or dextran.
4. A drug delivery composition according to Claim 3 wherein the microspheres are starch microspheres.
5. A drug delivery composition according to Claim 1 wherein the microsphere material is cross-linked.
6. A drug delivery composition according to Claim 1 wherein the microspheres have been heated to stabilize the microspheres.
7. A drug delivery composition according to Claim 1 additionally comprising an absorption enhancer.
8. A drug delivery composition according to Claim 7 wherein the absorption enhancer is a surfactant.
9. A drug delivery composition according to Claim 1 wherein the drug is a biologically active peptide.
10. A drug delivery composition according to Claim 9 wherein the peptide is insulin or calcitonin.

11. A system for intranasal drug delivery comprising a drug delivery composition according to Claim 1 and a container having an orifice through which the composition can be delivered to the nasal mucosa in a gas stream.

12. A system according to Claim 11 wherein the system is such that, in use, the product of the flow rate and the square of the microsphere aerodynamic diameter is greater than  $2000 \mu\text{m}^2.\text{litres/min}$ .

13. A method of delivering a drug to the nasal mucosa, comprising introducing a gas stream containing a composition according to Claim 1 into the nose.

14. A method of treating diabetes comprising introducing a gas stream containing a composition according to Claim 1 wherein the systemically active drug is insulin into the nose.

15. The drug delivery composition of claim 1 wherein the microspheres comprise a material or ester thereof selected from the group consisting of polyvinyl alcohol, polylactide-co-glycolide, hyaluronic acid, gellan gum and pectin.

16. The drug delivery composition of claim 1 wherein the microspheres comprise a material selected from the group consisting of hydroxyethyl starch, hydroxypropyl starch, carboxymethyl starch, cationic starch, acetylated starch, phosphorylated starch and grafted starch.

17. A method for systemically delivering an active drug to a mammal, the method comprising:

a) providing a composition comprising a plurality of bioadhesive microspheres and an active drug, wherein at least 90 wt % of the microspheres in the composition have a diameter between  $0.1 \mu\text{m}$  and  $10 \mu\text{m}$ ; and

b) administering the composition to a mammal intranasally thereby to systemically delivery a therapeutically effective amount of the drug to the mammal.

18. The method of claim 17 wherein the microspheres are prepared from a material that will gel in contact with the mucosal surface.

U.S.S.N. 08/359,937  
Filed: December 20, 1994  
SUPPLEMENTAL RESPONSE

19. The method of claim 17 wherein the microspheres comprise a material selected from the group consisting of starch, gelatin, albumin, collagen and dextran.
20. The method of claim 19 wherein the microspheres comprise starch.
21. The method of claim 17 wherein the microsphere material is cross-linked prior to step b).
22. The method of claim 17 wherein the microspheres are heated to stabilize the microspheres prior to step b).
23. The method of claim 17 the composition provided in step a) further comprises an absorption enhancer.
24. The method of claim 23 wherein the absorption enhancer is a surfactant.
25. The method of claim 17 wherein the drug is a biologically active peptide.
26. The method of claim 25 wherein the peptide is insulin or calcitonin.
27. The method of claim 17 wherein the microspheres comprise a material or ester thereof selected from the group consisting of polyvinyl alcohol, polylactide-co-glycolide, hyaluronic acid, gellan gum and pectin.
28. The method of claim 17 wherein the microspheres comprise a material selected from the group consisting of hydroxyethyl starch, hydroxypropyl starch, carboxymethyl starch, cationic starch, acetylated starch, phosphorylated starch and grafted starch.